Pharmacology

Letter by Zhao Regarding Article, “Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial” Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response Key Patient Messages: 2025 Acute Coronary Syndromes Guideline State of the Art: Evaluation and Medical Management of Nonobstructive Coronary Artery Disease in Patients With Chest Pain Reduction of Thrombus Burden With Short‐Term, Low‐Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE‐ARMYDA 7 Randomized Trial Clopidogrel Versus Aspirin Beyond 30 Days: Different Drugs, Same Outcomes? Empagliflozin Improves Cardiomyocyte Function in Phospholamban‐R14del Cardiomyopathy by Regulating Calcium/Calmodulin‐Stimulated Protein Kinase II Activity and Apoptosis Letter by Kornelius Regarding Article, “Cardiovascular Disease in Anabolic Androgenic Steroid Users” Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes